MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV… Read More
PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training(1) PiaSky® (crovalimab for injection) has the potential to… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents… Read More
According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to oral corticosteroids (OCS) before beginning biologic therapy. ACTIONS was carried out by… Read More
TORONTO, ON – Sanofi Canada announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi’s Canada Country Council, which manages the… Read More
